ClinicalTrials.gg

Program

QCZ484

A development code.

In Novartis's pipeline, AGT siRNA. Its studies are mostly in Hypertension · Hypercholesterolemia, led by Novartis.

Furthest: phase 2, since Mar 3, 20254 company-led studies, 3 open or runningNext primary completion: Apr 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis43 open or runningphase 2since Mar 3, 2025Mar 3, 2025Apr 28, 2027phase 2 · NCT07610278
  • Named in Novartis’s own pipeline as QCZ484, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2025First study: phase 2 study in HypertensionFirst studyNCT06857955 · 396 enrolled · United States, Japan, Singapore
  2. Mar 25, 2025Phase 1 study in HypertensionNCT06905327 · 56 enrolled · Australia, New Zealand
  3. Apr 15, 2026Phase 2 study in HypertensionNCT07543120 · 323 planned · United States, Japan, Singapore
  4. May 20, 2026Phase 2 study in HypercholesterolemiaNCT07610278 · 120 planned · United States

Ahead

  1. Apr 28, 2027Primary completion: phase 2 study in HypercholesterolemiaNCT07610278
  2. May 7, 2031Primary completion: phase 2 study in HypertensionNCT07543120

TargetBeta

“AGT siRNA”the company's pipeline, read by Claude · source

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07610278Hypercholesterolemia · United States2RecruitingApr 28, 2027120
NCT07543120Hypertension · United States, Japan, Singapore2RecruitingMay 7, 2031323
NCT06905327Hypertension · Australia, New Zealand1CompletedSep 25, 202456
NCT06857955Hypertension · United States, Japan, Singapore2Active, not recruitingSep 17, 2026396

How it is read

Names in the registry

  • “QCZ484”, 4 entries

Codes read as this program: QCZ484.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
QCZ484 (Novartis): development program | ClinicalTrials.gg